Coagulation Protein Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major coagulation protein disorders markets are expected to exhibit a CAGR of 7.6% during 2024-2034.
The coagulation protein disorders market has been comprehensively analyzed in IMARC's new report titled "Coagulation Protein Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coagulation protein disorders are a group of medical conditions characterized by abnormalities in the blood clotting process. This can result in prolonged bleeding and difficulty forming stable blood clots, leading to excessive and potentially life-threatening bleeding after even minor injuries or surgeries. The symptoms of these ailments often include easy bruising, frequent nosebleeds, heavy or prolonged menstrual bleeding in females, and persistent bleeding after dental procedures. In more severe cases, spontaneous joint or muscle bleeding can occur, leading to pain and swelling. Individuals suffering from these conditions may also experience gastrointestinal bleeding and blood in their urine. The diagnosis of coagulation protein disorders typically involves a combination of medical history assessment, family history evaluation, and specialized laboratory tests. These investigations measure the levels and functionality of various clotting factors, such as the von Willebrand factor, factor VIII, factor IX, and others. Genetic testing is also performed to identify specific gene mutations responsible for the disorder.
The increasing prevalence of genetic variations or immune dysfunction that impact the production or functioning of the proteins involved in the clotting process is primarily driving the coagulation protein disorders market. In addition to this, the inflating utilization of efficacious treatment modalities, such as factor replacement therapy, antifibrinolytic agents, and desmopressin, is also creating a positive outlook for the market. These therapies aim to replace the missing clotting factors or stimulate their production, thereby effectively managing the bleeding risk and improving patients' quality of life. Moreover, the widespread adoption of physical therapies and specialized exercise regimens in order to boost joint health, enhance muscular strength, and minimize bleeding episodes is further bolstering the market growth. Apart from this, the rising usage of novel interventions like gene therapy, since it involves inserting a functional gene into the genome to permanently rectify the genetic anomalies that lead to inadequate production of clotting factors, is acting as another significant growth-inducing factor. Furthermore, the ongoing advancements in diagnostic techniques, including next-generation sequencing and genetic counseling, which offer a comprehensive approach to patient care by providing early and accurate diagnosis of the conditions, are expected to drive the coagulation protein disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the coagulation protein disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coagulation protein disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coagulation protein disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the coagulation protein disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the coagulation protein disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current coagulation protein disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the coagulation protein disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the coagulation protein disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the coagulation protein disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of coagulation protein disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with coagulation protein disorders across the seven major markets?
What is the size of the coagulation protein disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of coagulation protein disorders?
What will be the growth rate of patients across the seven major markets?
Coagulation Protein Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for coagulation protein disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coagulation protein disorders market?
What are the key regulatory events related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by status related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by phase related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by route of administration related to the coagulation protein disorders market?
The coagulation protein disorders market has been comprehensively analyzed in IMARC's new report titled "Coagulation Protein Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coagulation protein disorders are a group of medical conditions characterized by abnormalities in the blood clotting process. This can result in prolonged bleeding and difficulty forming stable blood clots, leading to excessive and potentially life-threatening bleeding after even minor injuries or surgeries. The symptoms of these ailments often include easy bruising, frequent nosebleeds, heavy or prolonged menstrual bleeding in females, and persistent bleeding after dental procedures. In more severe cases, spontaneous joint or muscle bleeding can occur, leading to pain and swelling. Individuals suffering from these conditions may also experience gastrointestinal bleeding and blood in their urine. The diagnosis of coagulation protein disorders typically involves a combination of medical history assessment, family history evaluation, and specialized laboratory tests. These investigations measure the levels and functionality of various clotting factors, such as the von Willebrand factor, factor VIII, factor IX, and others. Genetic testing is also performed to identify specific gene mutations responsible for the disorder.
The increasing prevalence of genetic variations or immune dysfunction that impact the production or functioning of the proteins involved in the clotting process is primarily driving the coagulation protein disorders market. In addition to this, the inflating utilization of efficacious treatment modalities, such as factor replacement therapy, antifibrinolytic agents, and desmopressin, is also creating a positive outlook for the market. These therapies aim to replace the missing clotting factors or stimulate their production, thereby effectively managing the bleeding risk and improving patients' quality of life. Moreover, the widespread adoption of physical therapies and specialized exercise regimens in order to boost joint health, enhance muscular strength, and minimize bleeding episodes is further bolstering the market growth. Apart from this, the rising usage of novel interventions like gene therapy, since it involves inserting a functional gene into the genome to permanently rectify the genetic anomalies that lead to inadequate production of clotting factors, is acting as another significant growth-inducing factor. Furthermore, the ongoing advancements in diagnostic techniques, including next-generation sequencing and genetic counseling, which offer a comprehensive approach to patient care by providing early and accurate diagnosis of the conditions, are expected to drive the coagulation protein disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the coagulation protein disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coagulation protein disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coagulation protein disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the coagulation protein disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the coagulation protein disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current coagulation protein disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report
Key Questions Answered in this Report
Market Insights
How has the coagulation protein disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the coagulation protein disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the coagulation protein disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of coagulation protein disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of coagulation protein disorders by type across the seven major markets?
How many patients are diagnosed (2018-2034) with coagulation protein disorders across the seven major markets?
What is the size of the coagulation protein disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of coagulation protein disorders?
What will be the growth rate of patients across the seven major markets?
Coagulation Protein Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for coagulation protein disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coagulation protein disorders market?
What are the key regulatory events related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by status related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by phase related to the coagulation protein disorders market?
What is the structure of clinical trial landscape by route of administration related to the coagulation protein disorders market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COAGULATION PROTEIN DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COAGULATION PROTEIN DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COAGULATION PROTEIN DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 COAGULATION PROTEIN DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COAGULATION PROTEIN DISORDERS - UNMET NEEDS
10 COAGULATION PROTEIN DISORDERS - KEY ENDPOINTS OF TREATMENT
11 COAGULATION PROTEIN DISORDERS - MARKETED PRODUCTS
11.1 List of Coagulation Protein Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Eloctate (Efmoroctocog alfa) - Bioverativ/Swedish Orphan Biovitrum
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adynovate (Rurioctocog alfa pegol) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Hemlibra (Emicizumab-Kxwh) - Chugai Pharmaceutical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Afstyla (Lonoctocog alfa) - CSL
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Jivi (Damoctocog alfa pegol) - Bayer HealthCare
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 COAGULATION PROTEIN DISORDERS - PIPELINE DRUGS
12.1 List of Coagulation Protein Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 PF-06741086 - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Concizumab - Novo Nordisk
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SerpinPC - ApcinteX
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COAGULATION PROTEIN DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COAGULATION PROTEIN DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COAGULATION PROTEIN DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Coagulation Protein Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Coagulation Protein Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Coagulation Protein Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Coagulation Protein Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Coagulation Protein Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Coagulation Protein Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Coagulation Protein Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Coagulation Protein Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Coagulation Protein Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Coagulation Protein Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Coagulation Protein Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Coagulation Protein Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Coagulation Protein Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Coagulation Protein Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Coagulation Protein Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Coagulation Protein Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Coagulation Protein Disorders - Access and Reimbursement Overview
16 COAGULATION PROTEIN DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COAGULATION PROTEIN DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COAGULATION PROTEIN DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COAGULATION PROTEIN DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COAGULATION PROTEIN DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COAGULATION PROTEIN DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 COAGULATION PROTEIN DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COAGULATION PROTEIN DISORDERS - UNMET NEEDS
10 COAGULATION PROTEIN DISORDERS - KEY ENDPOINTS OF TREATMENT
11 COAGULATION PROTEIN DISORDERS - MARKETED PRODUCTS
11.1 List of Coagulation Protein Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Eloctate (Efmoroctocog alfa) - Bioverativ/Swedish Orphan Biovitrum
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adynovate (Rurioctocog alfa pegol) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Hemlibra (Emicizumab-Kxwh) - Chugai Pharmaceutical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Afstyla (Lonoctocog alfa) - CSL
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Jivi (Damoctocog alfa pegol) - Bayer HealthCare
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 COAGULATION PROTEIN DISORDERS - PIPELINE DRUGS
12.1 List of Coagulation Protein Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 PF-06741086 - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Concizumab - Novo Nordisk
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SerpinPC - ApcinteX
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COAGULATION PROTEIN DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COAGULATION PROTEIN DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COAGULATION PROTEIN DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Coagulation Protein Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Coagulation Protein Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Coagulation Protein Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Coagulation Protein Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Coagulation Protein Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Coagulation Protein Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Coagulation Protein Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Coagulation Protein Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Coagulation Protein Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Coagulation Protein Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Coagulation Protein Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Coagulation Protein Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Coagulation Protein Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Coagulation Protein Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Coagulation Protein Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Coagulation Protein Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Coagulation Protein Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Coagulation Protein Disorders - Access and Reimbursement Overview
16 COAGULATION PROTEIN DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COAGULATION PROTEIN DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COAGULATION PROTEIN DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
